関連する実験動画

Updated: Sep 8, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

RNF217- KEAP1- NRF2フィードバックループは,食道状細胞癌におけるフェロプトーシスを阻害することによって,治療抵抗性を授与する

Sifen Wang¹, Chao Zhang², Sha Zhou³

¹State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Guangdong Esophageal Cancer Institute, Guangzhou, China; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy

|September 5, 2025

まとめ

この研究では,環指タンパク質217 (RNF217) がフェロプトーシスを調節し,食道状細胞癌 (ESCC) の化学放射線療法耐性に影響を与えることを明らかにしました. RNF217,KEAP1,NRF2を含むフィードバックループは,ESCC治療の潜在的な治療目標を提供します.

科学分野:

腫瘍学
分子生物学
癌研究

背景:

治療抵抗は食道がん患者のアウトカムに大きな影響を及ぼします.
食道状細胞癌 (ESCC) の耐性メカニズムを理解することは,治療の有効性を改善するために極めて重要です.
制御された細胞死経路であるフェロプトーシスは,がん治療の感受性における役割としてますます認識されています.

研究の目的:

ESCCにおける化学放射線療法に対する耐性を誘発する重要な遺伝子と規制メカニズムを特定する.
ESCCにおける治療感受性におけるフェロプトーシスの役割を調査する.
環指タンパク質217 (RNF217) のフェロプトーシスと治療抵抗性における機能を明らかにする.

主な方法:

ESCCモデルにおけるフェロプトーシスと化学放射線療法に対する感受性の関連を調査した.
RNF217とケルチのようなECH関連タンパク質1 (KEAP1) の相互作用を特定し,特徴づけました.
核因子エリソイド2関連因子2 (NRF2) の安定性とシグナル伝達経路に対するRNF217の影響を評価した.
放射線条件下でのNRF2によるRNF217の転写調節を調べた.

主要な成果:

リングフィンガータンパク質217 (RNF217) は,フェロプトーシスの新しい調節剤として特定されました.
RNF217はKEAP1のユビキチン化と分解を促進し,NRF2の安定化につながります.
強化されたNRF2シグナリングは,ESCCにおけるフェロプトーシスと化学放射線治療に対する耐性を授与する.
NRF2は放射線を浴びるとRNF217の転写を正に調節し,フィードバックループを確立する.

結論:

新しいRNF217-KEAP1-NRF2フィードバックループは,ESCCにおける化学放射線療法に対する耐性を調節する.
この経路は,治療抵抗に寄与する以前に認識されていないメカニズムを表しています.
RNF217-KEAP1-NRF2軸をターゲットにすることで,ESCCにおける化学放射線療法抵抗を克服する戦略を提供することができる.

キーワード:

食道がんフェロプトーシス KEAP1 について RNF217 について治療に対する耐性

さらに関連する動画

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Modeling Oral-Esophageal Squamous Cell Carcinoma in 3D Organoids

Modeling Oral-Esophageal Squamous Cell Carcinoma in 3D Organoids

Published on: December 23, 2022

関連する概念動画

NF-κB-dependent Signaling Pathway

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Transducer Mechanism: Nuclear Receptors

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.